Non-formulary **macitentan** (**Opsumit®**) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Pulmonologist or Cardiologist
  - **AND** -
- Diagnosis of pulmonary arterial hypertension World Health Organization [WHO] Group I with WHO New York Heart Association Functional Class II, III or IV
  - **AND** -
- Documented treatment failure, intolerance or contraindication to bosentan (**Tracleer®**) AND ambrisentan (**Letairis®**) - **OR** -
  Diagnosis of moderate (Child-Pugh Class B) to severe (Child-Pugh Class C) hepatic impairment - **OR** -
  AST/ALT > 3 times the upper limit of normal
  
- Dose Change Only: Patient previously met criteria and is already taking the drug.

Notes:

- Macitentan is teratogenic and should not be used in pregnant females
- Macitentan is available through a restricted risk evaluation and mitigation strategy (REMS) program